27/12/2021 - General information
AELIS FARMA, a biotechnology company specializing in the treatment of brain disorders, announces today that AEF0217 has been administered to the first cohort of healthy volunteers, as part of a phase 1 clinical study to assess the safety, tolerability and the pharmacokinetic characteristics of its second drug candidate. The administration of AEF0217, using a dose in the expected therapeutic range, has good tolerability and demonstrates encouraging safety and plasma exposure characteristics for further clinical development. This phase 1 program is part of the European H2020 ICOD project (Improving COgnition in Down syndrome) which is led in collaboration with Hospital del Mar Medical Research Institute (IMIM) in Barcelona, and Prof. Raphael de la Torre Fornell, coordinator of the project and the principal investigator of the study. In February 2021, the ICOD project received funding of €6m from the European Commission to finance the clinical development of AEF0217 for the treatment of cognitive deficits linked to Down syndrome.
20/12/2021 - General information
The urgent need to find treatments for a large number of degenerative diseases has led a group of experts to develop a guide designed to accelerate new drug discoveries for neurological and psychiatric diseases. Project leads are Dr. Silvia Zaragoza Domingo, consultant and founder of Neuropsynchro, Barcelona, serving as coordinator collaborating with Drs. Jordi Alonso and Montserrat Ferrer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) and CIBERESP, and Dr. Manuel de Gracia, Facultat de Psicologia of Universitat de Girona (UdG). This guide was presented during the 34th Congress of the European Clinical Neurosychopharmacological College (ECNP) in Lisbon on 2-5 October and has been the group's priority project since it was established in 2018.
01/12/2021 - General information
The board of the Spanish Society of Pneumology and Thoracic Surgery has decided that the Hospital del Mar pneumologist and researcher at the Hospital del Mar Medical Research Institute will head up the committee responsible for managing and organising the society's policy documents. The Spanish Society of Pneumology and Thoracic Surgery (SEPAR), has appointed Dr. Esther Barreiro, a consultant in the Pneumology Department at Hospital del Mar and coordinator of the Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Research Group at the Hospital del Mar Medical Research Institute (IMIM), as coordinator of the SEPAR committee responsible for managing the regulations and recommendations that will be issued by the society. The appointment was made at the first meeting of the new SEPAR governing board.
Més informació "Dr. Esther Barreiro, coordinator of SEPAR regulations and recommendations"
16/11/2021 - General information
Researchers from the Hospital del Mar Medical Research Institute and CIBERES detect an increase in oxidative stress in these patients that may favour tumour development. Reduced levels of the potent antioxidant glutathione may be used as a new early biomarker of cancer in people with chronic respiratory disease. The risk of developing lung cancer increases in patients with COPD (Chronic Obstructive Pulmonary Disease), so understanding the cellular mechanism involved in tumour progression is key. Indeed, researchers from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and the CIBER on Respiratory Diseases (CIBERES) have just published a study in the journal Biomedicines that identifies the role of systemic oxidative and antioxidant markers, which are differentially expressed in these patients with chronic respiratory diseases, and are therefore involved in the development of lung cancer.
Més informació "Lung cancer patients with COPD have worse disease progression"
11/11/2021 - General information
The AECC has awarded 186 grants in 2021, totalling approximately 20 million euros. Two of these will benefit IMIM researchers, Teresa Lobo, who is receiving a postdoctoral grant, and Arnau Sabater, who has been able to participate in the laboratory internship programme. The Spanish Association Against Cancer awarded its 2021 research grants at a ceremony held on 11 November at its headquarters in Barcelona. In total, 186 projects and nearly 20 million euros have been allocated with the aim of continuing progress into cancer research, focusing on the patient and further increasing cancer survival. In this edition, two researchers linked to the Hospital del Mar Medical Research Institute (IMIM) will benefit from the grants.
Two projects by staff from the Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) have been awarded funding by the Spanish Society of Medical Oncology as part of its 2021 grants. The awards were presented on 13 October in Madrid and represent a new record for the organisation, with 44 scholarships and grants awarded with an endowment of nearly 1.4 million euros. All the money is earmarked for research and the training of medical professionals to improve the survival and quality of life of cancer patients.
18/10/2021 - General information
These new grants are linked to the Spanish Government's Recovery, Transformation and Resilience Plan and are co-financed by the European Union's Next-Generation funds. Four projects involving the IMIM will benefit. Four research projects led by or involving researchers from the Hospital del Mar Medical Research Institute (IMIM) will receive funding from the State Research Agency (Agència Estatal d'Investigació), as part of the aid promoted in Spanish and European plans linked to recovery from the COVID-19 pandemic. In total of, each project will receive just over 790,000 euros from these funds.
05/11/2021 - General information
A study led by the Colon and Rectal Surgery Unit, part of the Surgery Service at Hospital del Mar, has received two research grants, one from the Catalan Society of Surgery during the inaugural ceremony of the academic year on 15 October; and another from the Spanish Association of Coloproctology, during the organisation's conference, held from 20 to 22 October. The funding goes towards a multicentre project entitled 'Determining proangiogenic proteins in serum as a prognostic factor for recurrence after curative colon cancer surgery', led by Dr. Marta Pascual, head of the Colon and Rectal Surgery Unit, and Dr. Clara Téllez, a resident in the same department, in collaboration with Dr. Xavier Mayol, a researcher in the Cancer Research Programme at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
21/10/2021 - General information
The Spanish Society of Epidemiology (SEE) in its XVII edition has awarded the "Prize for research by young researchers. Edition 2021: Miguel Carrasco" to Natàlia Soldevila-Domènech, predoctoral researcher of the Integrative Pharmacology and Systems Neuroscience research group at IMIM, for the project "Analysis of trajectories of cognition evaluated in a continuous manner with cognitive training tasks in older adults at risk of Alzheimer 's disease". The work aims to evaluate the feasibility, validity and reliability of a measure of cognition obtained from the performance on self?administered computerized cognitive training tasks, and to identify and characterize subgroups of elderly individuals following a similar cognitive trajectory during the course of a preventive intervention for cognitive decline (PENSA Study).
20/10/2021 - General information
Patients with chronic kidney disease treated with bisphosphonates have a 15% higher risk of disease progression, although it is not linked to a higher rate of acute kidney injury, gastrointestinal events or hypocalcaemia. The study warns of the importance of assessing the stage of severity of CKD before prescribing bisphosphonates, as "They can worsen renal function and, in these cases, alternative treatments should be sought."
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
